Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
Joseph Therriault, Firoza Z. Lussier, Cécile Tissot, Mira Chamoun, Jenna Stevenson, Nesrine Rahmouni, Vanessa Pallen, Gleb Bezgin, Stijn Servaes, Peter Kunach, Yi‐Ting Wang, Jaime Fernandez‐Arias, Marie Vermeiren, Tharick A. Pascoal, Gassan Massarweh, Paolo Vitali, Jean‐Paul Soucy, Paramita Saha‐Chaudhuri, Serge Gauthie, Pedro Rosa‐Neto- Psychiatry and Mental health
- Neurology (clinical)
Abstract
Introduction
[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. However, no studies have yet published data on longitudinal Aβ accumulation measured with [18F]AZD4694.
Methods
We assessed 146 individuals who were evaluated with [18F]AZD4694 at baseline and 2‐year follow‐up. We calculated annual rates of [18F]AZD4694 change for clinically defined and biomarker‐defined groups
Results
Cognitively unimpaired (CU) older adults displayed subtle [18F]AZD4694 standardized uptake value ratio (SUVR) accumulation over the follow‐up period. In contrast, Aβ positive CU older adults displayed higher annual [18F]AZD4694 SUVR increases. [18F]AZD4694 SUVR accumulation in Aβ positive mild cognitive impairment (MCI) and dementia was modest across the neocortex
Discussion
Larger increases in [18F]AZD4694 SUVR were observed in CU individuals who had abnormal amyloid positron emission tomography levels at baseline. [18F]AZD4694 can be used to monitor Aβ levels in therapeutic trials as well as clinical settings, particularly prior to initiating anti‐amyloid therapies.